Abstract The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis and the meta-
analysis of individual participant data reported by non-small cell lung cancer (NSCLC) Meta …

Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …

Epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs) brought a
significant revolution in the treatment of non-small-cell lung cancer (NSCLC). In a short …

8502 Background: Median Overall survival (mOS) of stage IIIA resected NSCLC was 59.4
months (m) in CTONG 1104 adj gefitinib and 26.2 m in SAKK neoadjuvant chemo trial …

Purpose The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer …

The role of adjuvant tyrosine kinase inhibitors (TKIs) in non–small cell lung cancer (NSCLC)
is not well defined. Recent randomized controlled trials showed a disease-free survival …

EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …

Background Although neoadjuvant chemotherapy could improve survival outcome in
resectable non–small cell lung cancer (NSCLC), the efficacy of neoadjuvant targeted …

Background The role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in the adjuvant treatment of non-small cell lung cancer (NSCLC) has not been well …

Background Postoperative adjuvant cisplatin-based chemotherapy had been the standard
care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer …